The significant benefit Neu-1 inhibitors demonstrated in the study referenced above should provide some reassurance to their further exploration in clinical trials, as well as the realization that people dying from SARS-CoV-2 infection are dying from an unregulated immune response leading to the CRS and ARDS. Here, NEU1 is linked to congenital rubella syndrome.